Cosmetic & Aesthetic
Cosmetic procedures surging as rapid weight loss creates demand for body contouring.
Why GLP-1 Matters Here
Rapid weight loss produces predictable and specific body composition changes that drive cosmetic procedure demand. As subcutaneous fat is lost quickly, facial fat pads deflate, producing the "GLP-1 face" presentation widely documented in clinical and lay press, and skin loses its structural fill around the abdomen, arms, and thighs without the gradual elasticity adaptation that slower weight loss allows.
These are not vanity concerns; they are the expected physical consequences of losing significant body mass quickly.
What the Data Shows
The Johns Hopkins analysis of 6,200 aesthetic procedures from 2016 to 2024 found 54 percent annual growth in procedures among GLP-1 users following Wegovy and Mounjaro FDA approval.
Analysis
The strategic implication for the cosmetic industry is that this demand is largely additive: GLP-1 users represent a new patient cohort that did not previously present for body contouring procedures at this scale, not a substitution within existing procedure volume.
Recent Coverage
Research Findings
Curated citations from peer-reviewed studies and institutional research
Aesthetic procedures among GLP-1 users grew at nearly 54% per year following FDA approval of Wegovy and Mounjaro
% annual growth in aesthetic procedures among GLP-1 users post-FDA approval
Data Sources
Two-layer architecture: government fundamentals + curated research
Industry Fundamentals
ASPS Statistics — updated annual
Research Citations
Johns Hopkins / Aesthetic Surgery Journal
Peer-reviewed studies, investment bank analysis, and institutional surveys. Manually curated and updated monthly.
Get updates on Cosmetic & Aesthetic
Monthly data updates when this vertical's citations and industry data change.